Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 13/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | MPL | P40238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29296059 | 0.84 | USP1 (0.44) | USP1PTGS2PTGS1 | |
| SCHEMBL25298735 | 0.84 | USP1 (0.39) | USP1PTGS2PTGS1DGAT1 | |
| SCHEMBL25792147 | 0.84 | AR (0.40) | USP1PTGS2 | |
| SCHEMBL25792000 | 0.83 | PTGS2 (0.40) | USP1PTGS2PTGS1GAATSHR | |
| SCHEMBL25792162 | 0.82 | SCN9A (0.39) | USP1PTGS2GLAPOLBGAA | |
| SCHEMBL22143497 | 0.82 | USP1 (0.44) | USP1PTGS2PTGS1KDM4E | |
| SCHEMBL25791872 | 0.82 | USP1 (0.44) | USP1PTGS2PTGS1KDM4EDGAT1 | |
| SCHEMBL31138673 | 0.82 | USP1 (0.44) | USP1PTGS2PTGS1KDM4E | |
| SCHEMBL30320408 | 0.82 | USP1 (0.44) | USP1PTGS2PTGS1KDM4EDGAT1 | |
| SCHEMBL22121876 | 0.81 | PTGS2 (0.40) | USP1PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. | 2023-07-13 | — | — | US | disclosed |
| EP-4161494-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | KSQ Therapeutics, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219965-A1 | NITROGEN-CONTAINING FUSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 1 (USP1) INHIBITORS | USP1, USP8, USP7 | USP1 1/4885PTGS2 4515/4885PTGS1 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.